Increasing Use of GLP-1 Weight Loss Medications Among Obese Children in the US

Rising Use of GLP-1 Medications Among Young Obese Children in the United States

A new study led by NYU Langone Health indicates a remarkable surge in the use of GLP-1 receptor agonists, such as Saxenda, Wegovy, and Zepbound, for treating obesity in children under the age of 12 in the United States. Although the actual number of children prescribed these medications remains low, reports show that the figures soared by a staggering 310 times from 2019 to June 2026. This indicates an alarming trend in how young children’s obesity is being managed, especially as the nation grapples with a rising obesity epidemic among its youth.

The research reveals that only a small fraction of this age group, about 0.6 percent, were prescribed these medications compared to adolescents aged 12 to 17, where the figure was slightly higher at 0.9 percent. This discrepancy highlights a crucial observation that younger children, despite being eligible for GLP-1 treatments starting at age eight, are not receiving the same level of medical intervention as their teenage counterparts.

In the US, an estimated 20% of children are classified as obese, which is determined by their Body Mass Index (BMI) exceeding the 95th percentile for children of comparable age and sex, without the complication of diabetes present. The study analyzed the records of children aged 8 to 11 and found that the percentage of youngsters prescribed GLP-1s more than tripled, hitting 9.3% by 2026, compared to a mere 0.03% in 2019. Overall, 20,282 children within this age bracket have been given GLP-1 medications to combat obesity.

A significant aspect noted in the study is that girls were prescribed these medications more often than boys. Additionally, nearly all children receiving GLP-1 prescriptions had severe obesity, with approximately 93.7% exhibiting BMI levels much higher than their peers. Of these, over 65% grappled with obesity-related health issues, including high cholesterol, elevated blood pressure, and sleep apnea, showcasing the serious implications of childhood obesity.

Dr. Babak J. Orandi, an obesity medicine specialist and lead investigator of the study, commented, "Our study offers the first national overview in young children of the use of GLP-1 drugs to fight the obesity epidemic in the United States. While the absolute numbers of children under the age of 12 receiving GLP-1 treatment is still low, GLP-1 use is accelerating rapidly." He stressed that while the medications are effective tools for treating obesity and its metabolic complications, it's essential that the concerns around their use—especially related to children—are thoughtfully managed.

Despite hesitations from some parents regarding the prescription of weight loss medications for young children, failing to provide these treatments has its own long-term health risks. These risks include a higher likelihood of chronic diseases such as diabetes, hypertension, and liver ailments developing in early adulthood. Alarmingly, the study found that a quarter of the young children prescribed GLP-1s were prediabetic, which puts them at increased risk for illnesses linked to obesity.

The research also identifies a troubling trend regarding economic disparities in healthcare access. It was found that children from upper-income communities were 55% more likely to be prescribed GLP-1 medications compared to those from poorer backgrounds. Dr. Allan B. Massie, co-senior author of the study, highlighted the growing divide in access to obesity medications. He asserted that as the use of GLP-1 medications increases, it is crucial for physicians and policymakers to guarantee that all children suffering from obesity can access these treatments, regardless of their socioeconomic status.

In conclusion, the NYU Langone study emphasizes the pressing need for careful monitoring of GLP-1 treatments among children and aims to address disparities in treatment access as the prevalence of obesity continues to rise. With ongoing clinical trials targeting younger populations, including children as young as six, there is hope for better-guided treatment methodologies that can inform both parents and healthcare professionals alike in combating childhood obesity effectively.

Healthcare professionals agree on the importance of continuing research to ensure the ongoing safety and efficacy of these medications. By addressing the implications of childhood obesity, especially in relation to socioeconomic factors, the healthcare system can better support the younger population facing this significant health challenge.